INVA8001 Publication
INVA8001, a Novel and Highly Selective Chymase Inhibitor, Ameliorates Liver Inflammation, Fibrosis, and Hyperplasia in Mdr2 Knockout Mice / Nov, 2025/https://www.biorxiv.org/content/10.1101/2025.11.18.688305v1.full.pdf
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
InveniAI to Participate in the Truist Securities…
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic …
InveniAI to Participate in the Truist Securities… Read More »
Kyowa Hakko Kirin signs AI drug R&D deal with InveniAI
Kyowa Hakko Kirin signs AI drug R&D deal with InveniAI
